The Starting Material Decision That Shapes Your Entire Workflow
If you’re developing a cell therapy — whether CAR-T, gene therapy, or adoptive cell transfer — you’ll need leukopaks. And early in your program, you’ll face a decision that affects everything from scheduling flexibility to cell recovery to regulatory strategy: do you work with fresh or cryopreserved leukopaks?
This isn’t a trivial preference. The choice cascades through your manufacturing workflow, influences your process development timeline, and can determine whether your clinical supply chain actually works at scale. Here’s what the decision actually involves.
Fresh Leukopaks: Maximum Viability, Maximum Logistics Pressure
A fresh leukopak is collected from a healthy donor via leukapheresis and shipped to your facility without cryopreservation — typically arriving within 24 hours of collection. This means the cells have never been frozen, never exposed to cryoprotectant, and retain their native activation state and viability.
The advantages are real. Fresh leukopaks consistently deliver the highest viability (often >95%), the most cells per collection, and the most representative starting material for process development. If your manufacturing protocol was optimized using fresh material, your established parameters — activation kinetics, transduction efficiency, expansion curves — will be most reproducible with fresh material.
But fresh comes with constraints. The clock starts at collection, and you typically have 24-36 hours before viability begins to decline meaningfully. Your lab must be staffed, prepped, and ready to receive and process the material when it arrives. Delays — whether from shipping disruptions, scheduling conflicts, or equipment issues — can compromise the entire collection.
For early-stage R&D where you control the timeline and can coordinate closely with your supplier, fresh leukopaks are often the preferred choice.
Cryopreserved Leukopaks: Flexibility Without Starting Over
Cryopreserved leukopaks are collected, processed, and frozen using controlled-rate protocols with validated cryopreservation media. The resulting product can be stored in liquid nitrogen vapor phase indefinitely and thawed when your manufacturing slot is ready.
The scheduling flexibility is the headline benefit, but there are others. Cryopreserved leukopaks enable inventory building — you can bank material from multiple donors ahead of manufacturing campaigns, ensuring you’re not dependent on same-day collection logistics during critical runs. For clinical manufacturing, this can mean the difference between hitting your enrollment timeline and waiting weeks for donor availability.
The trade-off is a modest reduction in post-thaw viability (typically 70-85% depending on the product and thaw protocol) and some cell loss during the freeze-thaw cycle. Most established CAR-T and gene therapy manufacturing protocols have been adapted to work with cryopreserved starting material, and many FDA-approved cell therapies use cryopreserved leukopaks in their commercial manufacturing processes.
If you’re bridging from research to clinical manufacturing — or if your manufacturing facility isn’t co-located with your collection sites — cryopreserved leukopaks are often the more practical choice.
How the Decision Affects Downstream Processing
The impact of fresh vs. cryopreserved extends beyond the initial cell count. Consider these downstream effects:
T cell activation: Fresh T cells may activate more readily and uniformly, which can matter for transduction efficiency in CAR-T manufacturing. Cryopreserved T cells may require optimized activation conditions — slightly longer activation periods or adjusted cytokine concentrations.
Monocyte content: Fresh leukopaks contain a significant monocyte population that can interfere with T cell activation and expansion. Some manufacturers perform monocyte depletion or elutriation as a first step. In cryopreserved products, differential recovery rates during the freeze-thaw cycle naturally alter the cell composition, sometimes reducing the monocyte burden.
Process validation: Your manufacturing process must be validated with the same type of starting material you’ll use clinically. If you develop with fresh and switch to cryo for clinical supply, you may need additional comparability studies. Planning this decision early avoids expensive bridging work later.
What Your Supplier Should Provide Either Way
Regardless of which format you choose, certain quality attributes should be non-negotiable in your leukopak supply:
Comprehensive donor screening per FDA 21 CFR Part 1271, including testing for HIV, HBV, HCV, syphilis, and other communicable diseases. Every OrganaBio donor undergoes full regulatory screening with results documented in the Certificate of Analysis.
Characterized cell counts and differential — total nucleated cells, viability, and ideally a basic differential (lymphocyte, monocyte, granulocyte percentages) so you know what you’re working with before you start processing.
Validated cold chain — temperature monitoring during transit (for fresh) or validated cryopreservation with controlled-rate freezing profiles (for cryo). Breaks in the cold chain can destroy an otherwise perfect collection.
Lot-to-lot consistency — particularly important for process development work where variability in starting material translates directly into variability in your manufacturing data.
The Practical Recommendation
Many programs use both formats at different stages. Fresh leukopaks during early process development (to establish baseline performance with optimal material), transitioning to cryopreserved leukopaks as the process matures and clinical manufacturing logistics demand scheduling flexibility.
OrganaBio supplies both fresh and cryopreserved leukopaks from the same qualified, IRB-consented donor network, with the same screening standards and quality documentation. This makes comparability straightforward when you’re ready to bridge.
If you’re also sourcing isolated cell populations — T cells, NK cells, or PBMCs — these are available as cryopreserved products processed from the same leukopak collections, with full characterization data included.
Need help deciding which format fits your program? Talk to OrganaBio’s technical team — they’ve helped hundreds of cell therapy programs match starting material to manufacturing requirements.
